Full Press Release Details
Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine IMA203 Phase 1a Trial Targeting PRAME.
IMTX
Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine IMA203 Phase 1a Trial Targeting PRAME
Key Takeaway: Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine IMA203 Phase 1a Trial Targeting PRAME